Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer

LESSONS LEARNED. Vandetanib at a dose of 300 mg orally every day plus bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8, and 11 could be administered safely. Assessing outcomes in 17 patients with medullary thyroid cancer, investigators considered the combination to be more difficult to administe...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Del Rivero, Jaydira, Edgerly, Maureen, Ward, Jean, Madan, Ravi A., Balasubramaniam, Sanjeeve, Fojo, Tito, Gramza, Ann W.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Inc. 2018
Fag:
Clinical Trial Results
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324636/
https://ncbi.nlm.nih.gov/pubmed/30297385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0452
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker